NYMOX PHARMACEUTICAL CORPORATION Adjustments For Increase Decrease In Trade Account Payable
NYMOX PHARMACEUTICAL CORPORATION (NYMXF) reported Adjustments For Increase Decrease In Trade Account Payable of $1.24 million for the 12-month period ending 2024-12-31, per its 20-F filed 2025-06-03.
Financial Statements › Notes
ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable · last filed 2025-06-03
- NYMOX PHARMACEUTICAL CORPORATION adjustments for increase decrease in trade account payable for the quarter ending 2024-12-31 was -$22.00K, a 103.16% decline year-over-year.
- NYMOX PHARMACEUTICAL CORPORATION adjustments for increase decrease in trade account payable for the quarter ending 2023-12-31 was $696.00K.
- NYMOX PHARMACEUTICAL CORPORATION adjustments for increase decrease in trade account payable for the quarter ending 2023-09-30 was $217.00K, a 17.93% increase year-over-year.
- NYMOX PHARMACEUTICAL CORPORATION adjustments for increase decrease in trade account payable for the quarter ending 2023-06-30 was $83.00K.
| Period end | Adjustments For Increase Decrease In Trade Account Payable 3 month | Adjustments For Increase Decrease In Trade Account Payable 6 month | Adjustments For Increase Decrease In Trade Account Payable 9 month | Adjustments For Increase Decrease In Trade Account Payable 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$22.00K derived: 20-F 12 month − 6-K 9 month · filed 2025-06-03 | $1.24M 20-F · filed 2025-06-03 | ||
| 2024-09-30 | $1.26M 6-K · filed 2025-01-02 | |||
| 2023-12-31 | $696.00K derived: 20-F 12 month − 6-K 9 month · filed 2025-06-03 | $913.00K derived: sum of 2 quarters · filed 2025-06-03 | $996.00K derived: sum of 3 quarters · filed 2025-06-03 | $1.32M 20-F · filed 2025-06-03 |
| 2023-09-30 | $217.00K derived: 6-K 9 month − 6-K 6 month · filed 2025-01-02 | $300.00K derived: sum of 2 quarters · filed 2025-01-02 | $626.00K 6-K · filed 2025-01-02 | $418.00K derived: sum of 4 quarters · filed 2025-06-03 |
| 2023-06-30 | $83.00K derived: 6-K 6 month − 6-K 3 month · filed 2023-08-14 | $409.00K 6-K · filed 2023-08-14 | $201.00K derived: sum of 3 quarters · filed 2025-06-03 | $385.00K derived: sum of 4 quarters · filed 2025-06-03 |
| 2023-03-31 | $326.00K 6-K · filed 2023-05-12 | $118.00K derived: sum of 2 quarters · filed 2025-06-03 | $302.00K derived: sum of 3 quarters · filed 2025-06-03 | -$30.00K derived: sum of 4 quarters · filed 2025-06-03 |
| 2022-12-31 | -$208.00K derived: 20-F 12 month − 6-K 9 month · filed 2025-06-03 | -$24.00K derived: sum of 2 quarters · filed 2025-06-03 | -$356.00K derived: sum of 3 quarters · filed 2025-06-03 | $376.00K 20-F · filed 2025-06-03 |
| 2022-09-30 | $184.00K derived: 6-K 9 month − 6-K 6 month · filed 2023-11-15 | -$148.00K derived: sum of 2 quarters · filed 2023-11-15 | $584.00K 6-K · filed 2023-11-15 | $368.00K derived: sum of 4 quarters · filed 2024-08-29 |
| 2022-06-30 | -$332.00K derived: 6-K 6 month − 6-K 3 month · filed 2023-08-14 | $400.00K 6-K · filed 2023-08-14 | $184.00K derived: sum of 3 quarters · filed 2024-08-29 | $360.00K derived: sum of 4 quarters · filed 2024-08-29 |
| 2022-03-31 | $732.00K 6-K · filed 2023-05-12 | $516.00K derived: sum of 2 quarters · filed 2024-08-29 | $692.00K derived: sum of 3 quarters · filed 2024-08-29 | |
| 2021-12-31 | -$216.00K derived: 20-F 12 month − 6-K/A 9 month · filed 2024-08-29 | -$40.00K derived: sum of 2 quarters · filed 2024-08-29 | -$165.00K 20-F · filed 2024-08-29 | |
| 2021-09-30 | $176.00K derived: 6-K/A 9 month − 6-K 6 month · filed 2022-11-16 | $51.00K 6-K/A · filed 2022-11-16 | ||
| 2021-06-30 | -$125.00K 6-K · filed 2022-08-15 | |||
| 2020-12-31 | -$172.00K 20-F · filed 2023-05-02 |